Remitz A, Lauerma A I, Erkko P, Reitamo S
Department of Dermatology, Helsinki University Central Hospital, Finland.
Acta Derm Venereol. 1996 Jul;76(4):310-3. doi: 10.2340/0001555576310313.
Delayed-type hypersensitivity reactions to skin antigens are an indirect measure of cellular immune response. We studied in a double-blind manner whether clinically effective doses of cyclosporin A in palmoplantar pustulosis would diminish delayed-type hypersensitivity reactions in vivo. For testing delayed-type hypersensitivity, we applied intradermally a standardized panel of seven recall antigens and a vehicle control in 30 patients with palmoplantar pustulosis, and 28 were tested both at baseline and after 4 weeks. For 4 weeks 14 patients were treated with 2.5 mg/kg/day cyclosporin A and 14 patients with placebo. Cyclosporin A but not placebo caused a significant decrease in clinical disease parameters. In contrast, no significant differences in delayed-type hypersensitivity reactions between treatment groups were observed. The results do not support the view that the efficacy of low-dose cyclosporin A in dermatological disorders can be entirely explained by cyclosporin A's inhibitory actions on effector T-cells.
对皮肤抗原的迟发型超敏反应是细胞免疫反应的一种间接测量方法。我们以双盲方式研究了掌跖脓疱病中临床有效剂量的环孢素A是否会在体内减弱迟发型超敏反应。为了检测迟发型超敏反应，我们对30例掌跖脓疱病患者皮内注射一组标准化的七种回忆抗原和一个赋形剂对照，其中28例在基线时和4周后均进行了检测。14例患者接受4周的2.5mg/kg/天环孢素A治疗，14例患者接受安慰剂治疗。环孢素A而非安慰剂使临床疾病参数显著降低。相比之下，未观察到治疗组之间迟发型超敏反应有显著差异。结果不支持以下观点：低剂量环孢素A在皮肤病中的疗效可完全由其对效应T细胞的抑制作用来解释。
